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Apoptosis is a physiological process that is crucial to the growth
and development of multicellular organisms. Its dysregulation has
been linked to tumorigenesis (Mikulski, 1994; Wyllie, 1997).
Several proteins have been identified to be components of the
complex apoptosis machinery. Bcl-2, which is associated with 
the t(14;18) chromosomal breakpoint that occurs in follicular
lymphoma, was the first protein identified to possess anti-
apoptotic properties (Tsujimoto et al, 1985). Subsequently,
additional proteins that share structural homology with Bcl-2 have
been identified and characterized (Reed, 1994; McDonnell et al,
1996; Kroemer, 1997). These proteins, categorized as Bcl-2 family
proteins, have been widely studied in programmed cell death and
appear to possess either anti- or pro-apoptotic properties (Reed,
1994; McDonnell et al, 1996; Kroemer, 1997). In addition to the
Bcl-2 family proteins, activation of the tumour necrosis factor
(TNF) receptor family proteins by their respective ligands can
trigger apoptosis (Wallach et al, 1997; Ashkenazi and Dixit, 1998).
Initiation of apoptosis occur downstream of the ligand–receptor
interaction through proteolytic cascade that involve caspases
(Wallach et al, 1997; Ashkenazi and Dixit, 1998). Moreover, inter-
action between the two families of proteins mentioned above may
also occur. It has been shown that anti-apoptotic proteins Bcl-2
and Bcl-x can inhibit various TNF receptor-mediated apoptotic
events (Hermann et al, 1997; Srinivasan et al, 1998). Hence, coor-
dination of various components of different apoptosis pathways
may be necessary to ensure final execution of pro- or anti-
apoptotic signals.
Perturbation of Bcl-2 family proteins, and consequently apop-
tosis, may be important in mammary carcinogenesis. Over-
expression of the long form of the Bcl-x protein has been observed
in invasive breast cancer, and using Bcl-x protein expression as a
prognostic tool for monitoring breast cancer progression has been
suggested (Olopade et al, 1997). In addition, others have shown
that expression of Bax in normal breast tissues is significantly
higher than in malignant breast tissues (Bargou et al, 1995).
Exposure to oestradiol has been found to be associated with
increased risk in development of mammary tumour (Fishman et al,
1995). Given the involvement of Bcl-2 family proteins in tumori-
genesis (Reed, 1994; McDonnell et al, 1996; Kroemer, 1997),
modulation of the Bcl-2 family anti- or pro-apoptotic proteins by
oestradiol may play a critical role in the mammary carcinogenesis.
Recent work has indicated a potential role for 17b-oestradiol in
modulation of Bcl-2 family proteins, such as the anti-apoptotic
protein Bcl-2 (Wang and Phang, 1995; Huang et al, 1997) and pro-
apoptotic protein Bak (Leung et al, 1998). These results appear to
correlate with the anti-apoptotic property of oestradiol (Kyprianou
et al, 1991). However, it remains unclear if various Bcl-2 family
proteins may be coordinately regulated by oestradiol. Given that
therapeutic and prevention strategies utilizing anti-oestrogens
have been actively explored (Jordan, 1998), a better understanding
of the role of oestradiol in modulating the Bcl-2 family protein-
related apoptosis pathways may benefit development of breast
cancer therapeutic and prevention strategies. To address the
possible complex interaction of oestradiol with apoptosis path-
ways and taking into consideration that oestradiol, functioning
through oestrogen receptor, can serve as transcriptional activator,
we (1) examined the effects of oestradiol on Bcl-2 family proteins
at both the message and protein levels and (2) asked whether
various pro- or anti-apoptotic proteins can be regulated by oestra-
diol in a coordinated fashion. Our results indicate that (1) Bcl-2
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and (2) 1 7b-oestradiol exert paradoxical e ffects on the anti-
apoptotic proteins Bcl-2 and Bcl-x(L).
MATERIALS AND METHODS
Chemicals
Progesterone, tamoxifen, dihydrotestosterone and 1 7b-oestradiol
were purchased from Sigma (St Louis, MO, USA). Recombinant
human insulin-like growth facto r-I (IGF-I) and recombinant
human epidermal growth factor (EGF) were obtained from
Promega (Madison, WI, USA). All other chemicals were from the
best sources available.
Cell culture
MCF-7 cells were cultured as previously described ( Wang and
Phang, 1995). Briefl y, 1 week before initiation of the experiment,
cells were switched to phenol red-free RPMI-1640 (Biofluids,
Rockville, MD, USA) supplemented with 5% charcoal dextran-
treated fetal bovine serum (CDS) (Hyclone Laboratories Inc.,
Logan, U T, USA), 2mMglutamine, 100 units ml–1 penicillin,
100m g ml–1 streptomycin,  1nMinsulin and  2ng ml –1 hydrocorti-
sone for 3 days. Subsequentl y, cells were switched to media
without insulin and hydrocortisone, and 1 day before treatment
cells were trypsinized and plated in phenol red-free RPMI-1640
containing  2mMglutamine, 100 units ml–1 penicillin, 10 0m g ml–1
streptomycin and 5% CDS.
Determination of cell number and apoptosis for MCF-7
cells
We used DNA fragmentation as the criteria for apoptotic cell
death. DNA fragmentation was measured using the cell death
enzyme-linked immunosorbent assay (ELISA) (Boehringe r,
Indianapolis, IN, USA). Cells ( 5 ´104 cell) were plated in each
well of 24-well plates. After treatment, the cells were washed once
with phosphate-bu ffered saline and 0. 5ml lysis bu ffer was added.
After a 30-min incubation the supernatant was recovered and
assayed for DNA fragments according to manufacture r’s protocol.
Additional plates identically treated as above were analysed for
cell number using the sulphorhodamine assay ( Wang and Phang,
1995). The OD 405 obtained from the DNA fragmentation assay
was then normalized for cell number and the results are expressed
relative to untreated control.
Total RNA isolation, multi-probe RNAase protection
assay and RT-PCR
MCF-7 cells were grown in 6-well Costar plates ( 2  ´106 cells
well–1), and total RNA was isolated as described previously ( Wang
and Phang, 1995). Multi-probe RNAase protection assay for Bcl-2
family and TNF receptor family protein were performed using the
RiboQuant RNase protection assay (Pharmingen, San Diego, CA,
USA) according to the manufacture r’s protocol. The template set
used were hAPO-2 for Bcl-2 family proteins. The protected frag-
ments were visualized by autoradiography and quantitated using a
phosphoimager (BioRad GS-360) respectivel y. Phosphoimager
readings were normalized for glyceraldehyde 3-phosphate de-
hydrogenase (GAPDH) content. Determination of Bcl-x mRNA
levels using semiquantitative reverse transcription polymerase
chain reaction ( RT-PCR) were performed as follows. First-strand
synthesis was performed using a  RT-PCR kit from Stratagene (CA,
USA) using 0.1–0. 5m g of total RNA. Subsequent cDNA amplifi-
cation was performed using the following primers for Bcl-x:
5¢ -AAT GTC TCA GAG CAA CCG GGA GCT G- 3¢ (forward
primer) and  5¢ -TCA TTT CCT ACT GAA GAG TGA GCC CA- 3¢
(reverse primer), primers for GAPDH were obtained from
Clontech (CA, USA). The conditions for PCR were as previously
described ( Wang and Phang, 1995) except 20 cycles were
performed in the presence of 1 0m Ci of [a-P32] dATP (300 0Ci
mmol–1) per reaction. The linearity of the amplification cycles was
confirmed by separate experiments. The PCR products were then
separated on a 2% agarose gel. The gel was dried and exposed to a
Kodak X-OMAT AR film or phosphoimager screen (BioRad,
Richmond, CA, USA). The amplified cDNA fragments were
visualized by autoradiography and quantitated using a phospho-
imager (BioRad GS-360) respectivel y. Phosphoimager readings
were normalized for GAPDH content. The Bcl-x primers were
designed to amplify both long (70 2bp) and short forms (48 8bp),
but the short form was not detectable under the conditions used.
Immunodetection of Bcl-2 family proteins levels
MCF-7 cells were plated in 100-mm dishes at  5  ´106 cells dish–1
and treatments were begun 2 4h after plating.  Treated cells were
harvested by washing once with phosphate-bu ffered saline (PBS),
pH 7.4, and scraping from the dish into 0. 5ml buffer (PBS, 
pH 7.4, 1% NP40, 0.5% sodium deoxycholate, 0.1% sodium
dodecyl sulphate (SDS) supplemented with protease inhibitors
(100m g ml–1 phenylmethyl sulphonyl fluoride,  1m g ml–1 apro-
tinin, 1m g ml–1 leupeptin,  1mMEDTA, 1m g ml–1 pepstatin). Cells
were then lysed by sonication on ice ( Tekmar Sonic Disrupto r,
30% powe r, 30s) to obtain cell lysate for  Western blotting. Protein
concentration of the cell lysate was determined by the Dc protein
assay (Bio-Rad, Richmond, CA, USA). Aliquots of cell lysate
containing 15–2 5m g of protein were separated on 10% SDS poly-
acrylamide gel electrophoresis (SDS- PAGE) (Novex, San Diego,
CA, USA) and electro-transferred to polyvinyldifluoride
membrane (Millipore, Bedford, MA, USA). The membranes were
then probed with antibody against Bcl-2 (Dako, Carpinteria, CA,
USA), Bcl-x (Santa Cruz Biotechnology Inc., Santa Cruz, CA,
USA), Bak (Upstate Biochemicals, Lake Placid, N Y, USA) or Bax
(Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) and
visualized with the enhanced chemiluminescence method (Pierce,
IL, USA).
RESULTS
Effects of 17b-oestradiol on cell number and apoptosis
in human breast cancer cell line MCF-7
Treatment of oestrogen receptor (ER)-positive MCF-7 cell with
oestradiol can result in increased cell numbers. As shown in Figure
1A, MCF-7 cell cultured in presence of 10–10 M17b-oestradiol for
48h resulted in significantly higher cell number than the untreated
control. This e ffect of 1 7b-oestradiol on cell number homeostasis
appeared exerted in part through a decrease in apoptosis. The
relative apoptotic index for cells cultured in presence of oestradiol
were significantly lower than cells cultured in absence of
17b-oestradiol (Figure 1B).
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mRNA expression
To further understand the mechanism underlying the effect of
oestradiol on apoptosis, we began by examining the effect of
17b-oestradiol on the Bcl-2 family proteins, essential components
of apoptosis pathways. Given that 17b-oestradiol can exert its
effect through interaction with ER and serve as transcriptional
factor, we initially examined the effects of oestradiol on the
mRNA levels of the Bcl-2 family proteins. Taking advantage of a
multi-probe RNAase protection assay, we compared mRNA
expression of Bcl-2 family proteins in cells cultured in presence
and absence of 17b-oestradiol (Figure 2). After normalization to
GAPDH, we found several differences between cells cultured in
the presence or absence of 17b-oestradiol. Unexpectedly we found
treatment of cells with 17b-oestradiol led to a decrease in the anti-
apoptotic protein Bcl-x mRNA levels (Figure 2A). Treatment with
17b-oestradiol also leads to alteration in another Bcl-2 family
proteins, Bak, which we have previously reported (Leung et al,
1998).
Concentration-dependent effects of 17b-oestradiol on
Bcl-x mRNA expression
Down-regulation of the anti-apoptotic protein Bcl-x mRNA, as
demonstrated above using multi-probe RNAase protection assay,
appears to contradict the anti-apoptotic property of oestradiol.
Therefore, to further confirm that treatment with 17b-oestradiol
indeed led to decreased levels of Bcl-x mRNA, we used a semi-
quantitative RT-PCR as an alternative method to assess this
17b-oestradiol suppresses Bcl-x(L) in MCF-7 cells 389
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Figure 1 Effects of 17b-oestradiol on cell number homeostasis. MCF-7
cells were cultured in the presence or absence of 17b-oestradiol (10–10 M) for
48 h. Cell number and apoptosis index determined as described in Materials
and Methods. (A) Comparison of cell number. (B) Comparison of apoptosis
index
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Figure 2 Effect of 17b-oestradiol on the mRNA levels of Bcl-2 family
proteins assessed using RNAase protection assay. MCF-7 cells were
cultured in the presence or absence of 17b-oestradiol (10–10 M) for 48 h, RNA
isolated and multi-probe RNAase protection assay performed as described in
Materials and Methods. Lane 1, control. Lane 2, oestradiol. M: untreated
probes
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Figure 3 Concentration-dependent effects of 17b-oestradiol on Bcl-x(L)
mRNA levels. MCF-7 cells were treated with the indicated concentrations of
17b-oestradiol for 120 h. Total RNA was isolated, and the Bcl-x(L) mRNA
level was determined as described in Materials and Methods. *Represents
value (from three separate treatments) significantly different from that of
control (P < 0.05, ANOVA)alteration in Bcl-x message. Consistent with the multi-probe
RNAase protection assay, Bcl-x mRNA as assessed by semi-
quantitative RT-PCR was significantly less in cells cultured in the
presence of 17b-oestradiol than in untreated controls (Figure 3). In
addition, the effect of 17b-oestradiol on Bcl-x mRNA levels
appeared to be concentration-dependent. Under these RT-PCR
conditions only the long form-Bcl-x(L), but not the short form-
Bcl-x(S) of Bcl-x, mRNA were detected.
Comparison of the effects of 17b-oestradiol on Bcl-x(L)
to other Bcl-2 family proteins
Having established an effect of oestradiol on Bcl-x(L) mRNA, we
further compared the effects of 17b-oestradiol on Bcl-x to several
other Bcl-2 family proteins at the protein levels using immuno-
detection. As illustrated in Figure 4, Bcl-x(L) protein increased 
in a time-dependent fashion. Treatment with 17b-oestradiol
suppressed the time-dependent increase in Bcl-x protein, and the
effects can be observed after 24 h. In contrast, treatment of MCF-7
cells with 10–10 M 17b-oestradiol resulted in a time-dependent
increase in expression of the anti-apoptotic protein Bcl-2. The
effects of 17b-oestradiol on Bcl-2 can also be seen after 24-h treat-
ment. Treatment with 17b-oestradiol resulted in suppression of the
increase in the pro-apoptotic protein Bak. The time course for
oestradiol’s effect on Bak appeared to be different from that of
Bcl-2 or Bcl-x. Significant changes in Bak expression were
detected only after 72 h treatment with 17b-oestradiol. In addition,
we also compared the concentration effects of 17b-oestradiol on
the Bcl-2 family proteins described above. As shown in Figure 5,
the threshold of responses of anti-apoptotic protein Bcl-2, Bcl-x
and pro-apoptotic proteins Bak, to 17b-oestradiol appeared to be
similar. Significant changes in all three proteins can be observed at
10–11 M 17b-oestradiol. There were no significant differences in
Bax protein at any time point or treatment.
Specificity and mechanism of 17b-oestradiol’s effect on
Bcl-x(L) in MCF-7 cells
As we observed a difference in Bcl-x(L) levels in cells cultured in
presence and absence of 17b-oestradiol, we asked whether this
change was unique to 17b-oestradiol and whether this is through
ER-dependent pathway. The effects of oestradiol on Bcl-x(L) was
compared to that of various steroid hormones or growth factors
with known biological effects on mammary cells. These factors
included: 17b-oestradiol (10–10 M), progesterone (10–9 M), dihydro-
testosterone (10–9 M), EGF (10 ng ml–1), or IGF-I (10 ng ml–1). As
illustrated in Figure 6, after a 5-day incubation, only treatment
with 17b-oestradiol resulted in the suppression of Bcl-x(L), while
other treatments did not alter Bcl-x(L) protein levels. The
inhibitory effects of 17b-oestradiol appeared to be executed
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Figure 4 Time-dependent effects of 17b-oestradiol on Bcl-2 family proteins.
MCF-7 cells were cultured in the presence and absence of 17b-oestradiol
(10–10 M) as described in Materials and Methods. Cell were harvested at the
indicated times and Bcl-2 family proteins determined by immunodetection as
described in Materials and Methods. C: control, E: 17b-oestradiol
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Figure 5 Concentration-dependent effects of 17b-oestradiol on Bcl-2 family
proteins. MCF-7 cells were cultured in the presence of varied concentrations
of 17b-oestradiol as described in Materials and Methods. Cells were
harvested at the indicated times and Bcl-2 family proteins determined by
immunodetection as described in Materials and Methods
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Figure 6 Effects of various steroid hormones and growth factors on Bcl-x(L)
protein levels. MCF-7 cells were cultured in 5% CDS with additional
supplements of various steroid hormones or growth factors. Bcl-x(L) protein
levels were determined as described in Materials and Methods. The
immunoblot represents one of three separate experiments. The lanes are: (1)
DHT, 10–9 M dihydrotestosterone; (2) PROG, 10–9 M progesterone; (3) C,
control; (4) E, 10–10 M 17b-oestradiol; (5) EGF, 10 ng ml–1 epidermal growth
factor; (6) IGF, 10 ng ml–1 insulin-like growth factor-I; (7) Tam, 10–6 M
tamoxifen; (8) Tam+E, 10–6 M tamoxifen plus 10–10 M 17b-oestradiol. Upper
panel: Bcl-x(L); lower panel: actinthrough ER-dependent pathways. Treatment of cells with the anti-
oestrogen tamoxifen (10–6 M) abolished the inhibitory effect of
17b-oestradiol on Bcl-x(L) expression (Figure 6).
DISCUSSION
Oestradiol is a known risk factor in the development of mammary
cancer (Fisherman et al, 1995); however, the mechanism by which
oestradiol exerts its effect is still unclear. Given the importance 
of apoptosis in tumorigenesis (Mikulski, 1994; Wyllie, 1997) and
recent works implicating alteration of apoptosis pathways in
mammary tumorigenesis (Bargou et al, 1995; Olopade et al, 1997),
modulation of apoptosis pathways by oestradiol can be an impor-
tant mechanism by which oestradiol can exert its effect on
mammary carcinogenesis. It has been established, by this labora-
tory and others (Teixeria et al, 1995; Wang and Phang, 1995), that
oestradiol induces proliferation of human mammary tumour cells
in vitro, and this effect is due in part to a decrease in apoptosis.
Figure 1 confirms that treatment of oestradiol can result in both
increased cell numbers and decreased apoptosis. To further under-
stand the mechanisms underlying the effect of oestradiol on apop-
tosis, it would be important to examine the effect of 17b-oestradiol
on the various components of apoptosis pathways. With respect to
components of apoptosis pathways much attention has been
focused on Bcl-2, which has been shown to have potent anti-apop-
totic effects on tumour cells (Reed, 1994; McDonnell et al, 1996;
Kroemer, 1997). However, Bcl-2 is just one protein in a complex
and diverse family of proteins which have been shown to have
either anti- or pro-apoptotic properties (Reed, 1994; McDonnell
et al, 1996; Kroemer, 1997). In addition, apoptosis has also been
shown to be regulated by another family of proteins, the TNF
receptor family (Wallach et al, 1997; Ashkenazi and Dixit, 1998).
The regulation of these separate pathways and how alterations in
expression of the various family members result in cell death is
complicated and remains largely unclear. To elucidate the roles of
oestradiol we began by investigating the effects of oestradiol on
the mRNA levels of the Bcl-2 family proteins.
Interestingly, in an initial screening using a multi-probe RNAase
protection assay (Figure 3) we observed that cells cultured in pres-
ence of 17b-oestradiol expressed lower levels of the anti-apoptotic
protein Bcl-x mRNA than the untreated controls. Since Bcl-x has
been shown to be anti-apoptotic (Hu et al, 1998; Srinivasan et al,
1998), down-regulation of Bcl-x(L) is at odds with the anti-
apoptotic effect of oestradiol. Therefore, we further investigated
the effect of oestradiol on Bcl-x. As shown in Figure 3, this effect
of 17b-oestradiol on Bcl-x mRNA was subsequently confirmed
by semi-quantitative RT-PCR and we found that treatment with
17b-oestradiol resulted in concentration-dependent changes in
Bcl-x(L) mRNA. The changes in Bcl-x(L) mRNA were reflected
at the protein level. As shown in Figures 4 and 5, treatment with
17b-oestradiol also resulted in lower levels of Bcl-x(L) protein.
The effect of 17b-oestradiol appeared to be suppression of a
temporal increase of Bcl-x(L) during culturing of MCF-7 cells.
The level of Bcl-x(L) increased during the culturing periods
(0–120 h), and the addition of 17b-oestradiol attenuated that
increase. The effect of 17b-oestradiol on Bcl-x(L) is in contrast
to the effects of 17b-oestradiol on another anti-apoptotic protein,
Bcl-2. Treatment with 17b-oestradiol resulted in an increase in
both Bcl-2 mRNA and protein levels. Treatment with 17b-
oestradiol also affected the pro-apoptotic proteins Bak and Bax
differently. Treatment with 17b-oestradiol resulted in down-
regulation of Bak, but exerted little effect on Bax, both at the
mRNA and protein levels. The concentration of 17b-oestradiol
that elicited an effect on the various Bcl-2 family proteins was
similar. However, there appeared to be a difference in temporal
changes of various Bcl-2 family proteins upon exposure to 17b-
oestradiol. While changes in Bcl-2 and Bcl-x(L) occurred as early
as 24 h, the effect on Bak appeared to occur after 72 h.
In order to demonstrate the specificity of 17b-oestradiol as well
as the mechanism of action, we compared the effects of oestradiol
to other steroid hormones and cytokines. The addition of proges-
terone and dihydrotestosterone did not alter Bcl-x(L) levels. Thus,
the effects of 17b-oestradiol on Bcl-x(L) appeared to be specific
among the steroid hormones. In addition, oestradiol is known to
affect growth factors, which are believed to be responsible for part
of the proliferative responses induced by oestradiol (de Cupis and
Favoni, 1997). Treatment with EGF or IGF-1 did not cause any
changes in Bcl-x(L) levels. Thus, oestradiol does not appear to
exert its effect on Bcl-x(L) indirectly through regulation of these
growth factors. These results on Bcl-x is similar to what we have
found for Bak (Leung et al, 1998) and Bcl-2 (TT Wang, unpub-
lished observations). To determine whether the ER was necessary
for oestradiol to exert its effect on Bcl-x(L), we treated cells with
the anti-oestrogen tamoxifen. As shown in Figure 6, addition of
tamoxifen negated the suppressive effects exerted by 17b-
oestradiol, supporting that the effect of 17b-oestradiol was
mediated through ER-dependent pathways. The effects of 17b-
oestradiol on the Bcl-2 family proteins may be indirect, there is no
apparent consensus of an oestrogen-responsive element in the
Bcl-x or the Bcl-2 promoter sequences (Grillot et al, 1997).
However, several other consensus sequences for various other
transcriptional factors are present. Oestradiol may thus exert its
effect indirectly through one or more of these pathways.
The present study and our previous work (Wang and Phang,
1995; Leung et al, 1998) clearly demonstrated that oestradiol
coordinately regulated the expression of several within the Bcl-2
family of proteins, and this occurs in an ER-dependent manner.
This supports our hypothesis that oestradiol may regulate apop-
tosis through its effect on Bcl-2 family proteins. However, since
oestradiol inhibited apoptosis (Figure 1) and Bcl-x is known to
possess anti-apoptotic property, the down-regulation of Bcl-x by
oestradiol is difficult to interpret. However, we speculate that up-
regulation of Bcl-x(L) may be associated with cell survival in the
absence of proliferative signals. Up-regulation of Bcl-x(L) in
absence of proliferative signal may serve to insure cell survival in
the absence of growth signals. In the presence of oestradiol,
however, the survival pathway may have been inactivated, thus
down-regulation of Bcl-x occurred. By contrast, the other anti-
apoptotic protein Bcl-2 may be associated with proliferative
responses so that the cells can prevent apoptosis and take full
advantages of proliferative signals induced by oestradiol. It is
interesting, in this light, to consider a recent study which has
shown that Bcl-x(L) is often over-expressed in ER-negative inva-
sive tumours (Olopade et al, 1997). This is consistent with the
current data, which show that Bcl-x(L) expression is higher in
absence of an oestradiol signal.
In summary, 17b-oestradiol exerted a differential effect on
Bcl-2 family proteins in ER-positive human breast cancer cell line
MCF-7. Interestingly, 17b-oestradiol appeared to exert a para-
doxical effect on the anti-apoptotic protein Bcl-2 and Bcl-x(L).
We proposed that different pathways may be involved in
regulation of Bcl-2 family proteins, and 17b-oestradiol may exert
an effect on these pathways.
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